October 7, 2009 (FinancialWire) — Rockwell Medical Technologies, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, reported it has added Jur Strobos M.D. to its scientific advisory boardl Rockwell’s SAB currently advises the company on clinical development for its proprietary iron-maintenance drug SFP, currently in FDA clinical development.

Robert L. Chioini, chairman, CEO and president of Rockwell, stated, “We are delighted to have Dr. Strobos join our SAB. Jur has significant experience as it pertains to both FDA clinical drug development and corporate drug development, and he knows the renal space particularly well. We expect his input will prove to be a great benefit to moving SFP through the FDA process.”

Dr. Strobos has extensive scientific and legal training as well as substantial management experience in the pharmaceutical industry. He served as the director of the Policy Research Staff in the Office of the Commissioner at the U.S. Food and Drug Administration. He worked closely with the Commissioner on regulatory policy, drug promotion, standards for review of clinical studies, drug and medical device review and approval, biological product and human tissue review and approval, international harmonization of review standards, electronic submissions, mammography quality, federal healthcare financing of investigational devices and informed consent. After practicing regulatory law in Washington, DC, Dr. Strobos held executive positions at three pharmaceutical firms as their VP of clinical research and regulatory affairs (two start-ups and one NYSE-listed company). His responsibilities included regulatory affairs, and nonclinical and clinical development of drugs, medical devices, and biological products. Dr. Strobos has been intimately engaged in the creation, filing, and regulatory issues involved in INDs, NDAs, PMAs, and BLAs, including the manufacturing, nonclinical, clinical and regulatory issues. Dr. Strobos has performed a pivotal role in the regulatory and/or clinical strategy of several marketed products, including Ferrlecit, the DePuy ACS Knee, Perlane, Solodyn, Restylane, Hectorol, ResQPOD, as well as many products currently under IND. Dr. Strobos received degrees from Johns Hopkins University (BA/Honors), the University of Chicago Pritzker School of Medicine and the University of Pennsylvania Law Schooll

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.